Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05540938 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Post-marketing Re-evaluation of WangBi Granules for Rheumatoid Arthritis

StatusRecruiting
PhasePhase 4
Started2023-05-23
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 20, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2025-01-17
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v5
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2025-06-01→2025-12-31
Completion date2025-06-01→2026-03-31
Start dateestimated 2023-04-15→confirmed 2023-05-23
Study sites0→1
2023-04-03
Study Status v4
Start date2023-02-15→2023-04-15
2023-02-03
Study Status v3
Start date2022-12-01→2023-02-15
2022-11-10
Study Status, Sponsor/Collaborators, Study Design v2
Start date2022-10-01→2022-12-01
Collaborators5 entries, revised
Peking Union Medical College Hospital The First Affiliated Hospital of Anhui University of Chinese Medicine Bethune International Peace Hospital Qilu Hospital of Shandong University First Teaching Hospital of Tianjin University of Traditional Chinese Medicine ChineseThe 980th Hospital of PLA GeneralJoint Logistics Support Force The Second Affiliated Hospital of Zhejiang Chinese Medical University Southwest Hospital, China
2022-09-29
Study Status, Sponsor/Collaborators v1
Collaborators+250 characters
The First Affiliated Hospital of Anhui University of Chinese Medicine Bethune International Peace Hospital Qilu Hospital of Shandong University First Teaching Hospital of Tianjin University of Traditional Chinese Medicine Chinese PLA General Hospital
2022-09-14
Original filing
The group used a randomized controlled trial to conduct a post-marketing re-evaluation study of Wangbi granules. The study was conducted to observe the degree of clinical remission in rheumatoid arthritis patients with low disease activity after standard methotrexate and tofacitinib citrate treatment, using a combination of Chinese and Western medicine treatment with Wangbi granules. The study aims to provide evidence-based medical evidence to improve the clinical efficacy of rheumatoid arthritis, enhance the depth of remission, and improve the diagnosis and treatment of rheumatoid arthritis.
Trial Details
NCT Number NCT05540938
Lead Sponsor China-Japan Friendship Hospital
Collaborators: Peking Union Medical College Hospital, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, The 980th Hospital of PLA Joint Logistics Support Force, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Southwest Hospital, China
Conditions Rheumatoid Arthritis
Enrollment 340 participants
Start Date 2023-05-23
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-20